|Table of Contents|

Comparison of the short-term efficacy of R2 and R-miniCHOP regimens in the treatment of elderly patients with B-cell non-Hodgkin' s lymphoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 06
Page:
932-937
Research Field:
Publishing date:

Info

Title:
Comparison of the short-term efficacy of R2 and R-miniCHOP regimens in the treatment of elderly patients with B-cell non-Hodgkin' s lymphoma
Author(s):
LIU Ping; LU Yinghao; ZHENG Lin; WANG Jianyu; CHEN Ying; WANG Jishi
The Affiliated Hospital of Guizhou Medical University,Guizhou Guiyang 550004,China.
Keywords:
B-cell non-Hodgkin's lymphoma; lenalidomide; rituximab; efficacy
PACS:
R733.4
DOI:
10.3969/j.issn.1672-4992.2025.06.007
Abstract:
Objective:To compare the recent efficacy and adverse effects of the R2 (lenalidomide+rituximab) and R-miniCHOP regimens in elderly patients with B-cell non-Hodgkin's lymphoma under preliminary observation.Methods:We retrospectively analyzed the clinical data of elderly (≥65 years old) patients treated with R2 (lenalidomide+rituximab) regimen (10 patients) or R-miniCHOP regimen (12 patients) with complete data from January 2022 to September 2023 in our hospital,and compared the therapeutic efficacy,the occurrence of adverse reactions,and the regression of disease between the two groups.Results:The overall response rate (ORR) was 60% in the R2 group and 50% in the R-miniCHOP group,with no statistical difference.The median follow-up time was 14 and 16.5 months,and there was no statistically significant difference in the 1-year OS rate (80% vs 83.3%,P＞0.05) and 1-year PFS rate (70% vs 66.7%,P＞0.05).The adverse reactions of the two groups were mainly hematological adverse reactions,and the incidence was statistically significant (P＜0.05).Conclusion:The recent efficacy of R2 and R-miniCHOP regimens in the treatment of elderly patients with B-cell non-Hodgkin' s lymphoma is similar,but the incidence of adverse reactions in the R2 group is low,safe and tolerable.

References:

［1］ ELISABETH S,GILLES S,ELIAS C,et al.B-cell non-Hodgkin lymphomas ［J］.Lancet,2024,403(10438):1791-1807.
［2］ 薛妞艳,孙凤玲,刘文博.弥漫大B细胞淋巴瘤骨髓侵犯的异质性与病理特征 ［J］.中国肿瘤临床与康复,2019,26(12):1448-1451. XUE NY,SUN FL,LIU WB.Heterogeneity and pathological features of bone marrow in vision in diffuse large B cell lymphoma ［J］.Chin J Clin Oncol Rehabil,2019,26(12):1448-1451.
［3］ ISSA DE,VAN DE SCHANS SAM,CHAMULEAU MED,et al.Trends in incidence,treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010 ［J］.Haematologica,2015,100(4):525-533.
［4］ ALLEN P.Diffuse large B-cell lymphoma in the elderly:current approaches［J］.Curr Oncol Rep,2020,22:1-10.
［5］ 赵志强,魏俏俏,范双龙,等.老年弥漫大B细胞淋巴瘤患者预后影响因素分析［J］.肿瘤研究与临床,2022,34(2):128-131. ZHAO ZQ,WEI QQ,FAN SL,et al.Analysis of factors affecting the prognosis of elderly patients with diffuse large B-cell lymphoma ［J］.Cancer Res Clin,2022,34(2):128-131.
［6］ 马晓松,汪步海,梁一晨,等.B细胞非霍奇金淋巴瘤靶向药物治疗研究进展 ［J］.现代肿瘤医学,2022,30(12):2272-2275. MA XS,WANG BH,LIANG YC,et al.Advances in targeted drug therapy for B-cell non-Hodgkin's lymphoma ［J］.Modern Oncology,2022,30(12):2272-2275.
［7］ 陈智丽,易婷,谭彪彬.利妥昔单抗联合CHOP方案治疗B细胞非霍奇金淋巴瘤的疗效观察 ［J］.中国肿瘤临床与康复,2022,29(01):48-50. CHEN ZL,YI T,TAN BB.Efficacy and safety of rituximab combined with CHOP regimen in the treatment of B-cell non-Hodgkin lymphoma ［J］.Chin J Clin Oncol Rehabil,2022,29(01):48-50.
［8］ 杨波,岳恺,朱晓果.利妥昔单抗联合改良CHOP方案治疗非霍奇金淋巴瘤的临床疗效 ［J］.癌症进展,2023,21(06):656-659. YANG B,YUE K,ZHU XG.Clinical efficacy of rituximab combined modified CHOP regimen in the treatment of non-Hodgkin lymphoma ［J］.Oncology Progress,2023,21(06):656-659.
［9］ 李巧佴,邹立群.老年弥漫大B细胞淋巴瘤的分层治疗策略 ［J］.国际肿瘤学杂志,2021,48(5):317-320. LI QE,ZOU LQ.Stratified therapeutic choices in elderly patients with diffuse large B-cell lymphoma ［J］.J Int Oncol,2021,48(5):317-320.
［10］ TILLY H,DA SILVA MG,VITOLO U,et al.Diffuse large B-cell lymphoma (DLBCL):ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up［J］.Ann Oncol,2015,26:v116-v125.
［11］ MCMILLAN A,MARTIN A,HAIOUN C,et al.Post relapse survival rates in diffuse large B-cell lymphoma［J］.Blood,2016,128(22):4204.
［12］ CUNNINGHAM D,HAWKES EA,JACK A,et al.Rituximab plus cyclophosphamide,doxorubicin,vincristine,and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma:a phase 3 comparison of dose intensification with 14-day versus 21-day cycles ［J］.Lancet,2013,381(9880):1817-1826.
［13］ LIOKA F,IZUMI K,KAMODA Y,et al.Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy ［J］.Int J Clin Oncol,2016,21(3):498-505.
［14］ 祝彪,向洪,甘茂周,等.减低剂量利妥昔单抗联合CHOP方案治疗老年弥漫性大B细胞淋巴瘤的疗效观察 ［J］.国际输血及血液学杂志,2016,39(2):93-99. ZHU B,XIANG H,GAN MZ,et al.Clinical outcome of reduced-dose rituximab combined with CHOP chemotherapy in treatment of diffused large B cell lymphoma for elderly patients ［J］.Int J Blood Transf Hematol,2016,39(2):93-99.
［15］ KAYAMORI K,SHONO K,ONODA M,et al.Efficacy and tolerability of rituximab and reduced-dose cyclophosPhamide,doxorubicin,vincristine,and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma［J］.Hematology,2019,24(1):52-59.
［16］ DI M,HUNTINGTON SF,OLSZEWSKI AJ.Challenges and opportunities in the management of diffuse large B-cell lymphoma in older patients［J］.Oncologist,2021,26(2):120-132.
［17］ WITZIG TE,VOSE JM,ZINZANI PL,et al.An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma ［J］.Ann Oncol,2011,22(7):1622-1627.
［18］ ZINZANI PL,PELLEGRINI C,ARGNANI L,et al.Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab ［J］.Haematologica,2016,101(9):e385-e386.
［19］ DREDGE K,HORSFALL R,ROBINSON SP,et al.Orally administered lenalidomide (CC-5013) is antiangiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro ［J］.Microvasc Res,2005,69(1-2):56-63.
［20］ ZHU D,CORRAL LG,FLEMING YW,et al.Immunomodulatory drugs Revlimid(lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation ［J］.Cancer Immunol Immun,2008,57(12):1849-1859.
［21］ VALLET S,PALUMBO A,RAJE N,et al.Thalidomide and lenalidomide:Mechanism-based potential drug combinations ［J］.Leukemia Lymphoma,2008,49(7):1238-1245.
［22］ CHONG E,AHMADI T,AQUI N,et al.Combination of lenalidomide and rituximab overcomes rituximab resistance in patients with indolent b-cell and mantle cell lymphomas［J］.Clin Cancer Res,2015,21(8):1835-1842.
［23］ RUBENSTEIN JL,GENG H,FRASER EJ,et al.Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma ［J］.Blood Adv,2018,2(13):1595-1607.
［24］ NOWAKOWSKI GS,HONG F,SCOTT DW,et al.Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US Intergroup Study ECOG-ACRIN E1412 ［J］.J Clin Oncol,2021,39(12):1329-1338.
［25］ 黄德鸿,李岱阳,项颖,等.来那度胺维持治疗在一线治疗缓解后弥漫大B细胞淋巴瘤患者中的应用 ［J］.癌症进展,2024,22(17):1891-1895,1899. HUANG DH,LI DY,XIANG Y,et al.Application of lenalidomide maintenance therapy in diffuse large B-cell lymphoma patients after first-line treatment response ［J］.Oncology Progress,2024,22(17):1891-1895,1899.
［26］ RAMCHANDREN R,JOHNSON P,GHOSH N,et al.The iR(2) regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL:A multicentre,non-randomised,open-label phase 2 study ［J］.EClinicalMedicine,2023,56:101779.
［27］ XU PP,SHI ZY,QIAN Y,et al.Ibrutinib,rituximab,and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma:a phase 2,single-arm study ［J］.The Lancet Healthy Longevity,2022,3(7):e481-e490.
［28］ 薛丹丹,陶洁.来那度胺联合利妥昔单抗治疗复发/难治性弥漫大B细胞淋巴瘤的研究进展 ［J］.国际输血及血液学杂志,2021,44(3):258-262. XUE DD,TAO J.Research progress of lenalidomide combined with rituximab in treatment of relapsed/refractory diffuse large B-cell lymphoma ［J］.International Int J Blood Transf Hematol,2021,44(3):258-262.
［29］ 郑鸿,褚玉丹,祝子华.改良R2方案治疗初治或复发难治性老年B细胞非霍奇金淋巴瘤的临床疗效和安全性 ［J］.肿瘤,2022,42(11):744-749. ZHENG H,CHU YD,ZHU ZH.Combination of lenalidomide and rituximab in treatment of the elderly patients with initially treated or relapsed and refractory B-cell non-Hodgkin's lymphoma:clinical efficacy and safety ［J］.Tumor,2022,42(11):744-749.

Memo

Memo:
National Natural Science Foundation of China(No.82160704);国家自然科学基金地区基金（编号：82160704）；贵州省卫生健康委科学技术基金项目（编号：gzwkj2021-158）；贵州医科大学附属医院国家自然科学基金培育计划项目资助（编号：gyfynsfc-2021-43）；贵州医科大学附属医院博士科研启动基金项目（编号：gyfybsky-2021-51）
Last Update: 1900-01-01